key: cord-1012654-nwpws2oh authors: Sathyanarayanan, Swaminathan P.; Hamza, Muhammad; Hamid, Khizar; Groskreutz, Dayna title: Cisatracurium-Associated Malignant Hyperthermia During Severe Sars-CoV-2 Infection date: 2021-08-10 journal: Am J Ther DOI: 10.1097/mjt.0000000000001437 sha: ee2d36d0de1b134ed0b63131d3430957bb300361 doc_id: 1012654 cord_uid: nwpws2oh nan To the Editor: Malignant hyperthermia (MH) is an uncommon but potentially life-threatening pharmacogenetic disorder that affects skeletal muscles. It is seen in response to volatile anesthetic agents and depolarizing neuromuscular blocker (NM blocker), succinylcholine. MH occurrence with a nondepolarizing NM blocker is a very rare phenomenon. Here, we report a case of cisatracurium-induced MH in an intensive care setting. A 60-year-old gentleman with a medical history significant for dyslipidemia and solitary kidney was hospitalized because of worsening shortness of breath. He tested positive for SARS-CoV-2 6 days before presentation. His vitals on presentation: oxygen saturation of 92% on heated high flow nasal cannula with FiO2 60%, blood pressure 130/80 mm Hg, heart rate 95/min, and respiratory rate 48/min. Physical examination was unremarkable except for coarse breath sounds. Computed tomography angiogram of the chest was negative for pulmonary embolism; however, it showed extensive bilateral ground-glass airspace opacities. He was started on dexamethasone, remdesivir, and broadspectrum antibiotics. His respiratory distress worsened, and he failed heated high flow nasal cannula and noninvasive ventilation. Thus, he was intubated and started on low tidal volume mechanical ventilatory support. He was started on dexmedetomidine, propofol, midazolam, and fentanyl infusions for sedation and pain control and was paralyzed with cisatracurium infusion for better ventilator compliance. Sixteen hours later, he developed rapid onset of high-grade fever of 106.6°F, tachycardia 130 beats/min, and ETCo2 (end-tidal carbon dioxide) increased to 48 mm Hg from 37 mm Hg. Laboratory evaluation showed pH of 7.28, pCO2 77 mm Hg, HCO3 35 mmol/L, and creatine kinase at 1003 U/L (ref 30-223). Serum creatinine and serum potassium increased to 1.4 mg/dL and 5.1mEq/dL from 1 mg/dL and 4.5mEq/dL, respectively. Blood cultures were negative for bacterial growth. MH was suspected, cisatracurium was stopped, and he was started on cooling blankets. Intravenous dantrolene 250 mg was administered, and his temperature came down to 101.5°F in 4 hours. Arterial blood gas improved to pH 7.39, pCO2 49 mm Hg, and HCO3 29 mmol/L after his symptoms resolved. Over the course of the next few days, his creatine kinase trended down. MH is a pharmacological disorder typically triggered by potent inhalational anesthetic agents such as halothane, isoflurane, sevoflurane, and the depolarizing muscle relaxant succinylcholine. 1 It results from disturbances in the calcium homeostasis within the skeletal muscles caused by these agents. Rarely, stressors such as vigorous exercise and heat can also be triggers in humans. The hypermetabolic crisis that results from MH leads to increased production of carbon dioxide (CO2) despite an increase in minute ventilation. 2 This is seen as increased end-tidal CO2 along with tachycardia which are the earliest signs. This is followed by muscle rigidity and a dramatic rapid increase in the core body temperature. Other features include severe acidosis, hyperkalemia, and a rise in creatine kinase levels sometimes resulting in rhabdomyolysis and acute tubular necrosis. 3 Our patient presented with highgrade fevers, increased CO2 production, and elevated creatine kinase; however, as he was chemically paralyzed, muscle rigidity was not appreciated which could have blunted the peak creatine kinase levels. MH may occur any time after administration of the triggering agent, but most commonly it is seen within 140 minutes after halogenated anesthetics and within 35 minutes after succinylcholine. 4 Most of the cases occur in the intraoperative or postoperative setting after administration of these agents. When it comes to muscle relaxants, existing literature indicates that MH is mostly triggered by the depolarizing neuromuscular blocker succinylcholine; however, there have been rare case reports of nondepolarizing NM blockers causing MH. 4, 5 There has only been one report of cisatracurium-induced MH reported before. 5 Interestingly both cases had acute respiratory distress syndrome raising suspicion for a possible association between MH and cisatracurium in patients with acute respiratory distress syndrome. The Naranjo score was calculated to be 7. Treatment of MH involves stopping the offending agent, using cooling blankets to bring the core temperature down, hyperventilation at 10 L/min 100% FiO2 to bring the ETCo2 down, and administration of dantrolene 2.5 mg/kg as a rapid intravenous bolus followed by every 5 to 10 minutes until the symptoms of MH are controlled and cardiac and respiratory status are stabilized. 6 This case report highlights the potential of nondepolarizing NM blockers to cause MH. Is there an association between COVID-19 mortality and the reninangiotensin system? A call for epidemiologic investigations SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor Enalapril attenuates downregulation of Angiotensin-converting enzyme 2 in the late phase of ventricular dysfunction in myocardial infarcted rat Localization of ACE2 in the renal vasculature: amplification by angiotensin II type 1 receptor blockade using telmisartan Kidney and lung ACE2 expression after an ACE inhibitor or an Ang II receptor blocker: implications for COVID-19 Antecedent Administration of angiotensin-converting REFERENCES Malignant hyperthermia: a review Malignant hyperthermia Malignant hyperthermia Delayed-onset malignant hyperthermia in association with rocuronium use A rare case of malignant hyperthermia due to cisatracurium Updated guide for the management of malignant hyperthermia